Topline
Johnson & Johnson is allowing Stop TB Partnership, a Switzerland-based nonprofit, to distribute a generic version of its tuberculosis drug SIRTURO, or bedaquiline, in low- and middle-income countries, a move that averts fears the drug will stay out of reach financially for many communities around the world.
Key Facts
Under an agreement announced Thursday, the nonprofit Global Drug Facility, an arm of Stop TB Partnership, will be able to tender, procure and supply generic versions of bedaquiline for most low- and middle-income countries, including countries where Johnson & Johnson’s patents remain in effect.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased